ICUD-EAU international consultation on bladder cancer 2012: Chemotherapy for urothelial carcinoma - Neoadjuvant and adjuvant settings

Cora N. Sternberg, Joaquim Bellmunt, Guru Sonpavde, Arlene O. Siefker-Radtke, Walter M. Stadler, Dean F. Bajorin, Robert Dreicer, Daniel J. George, Matthew I. Milowsky, Dan Theodorescu, David J. Vaughn, Matthew D. Galsky, Mark S. Soloway, David I. Quinn

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Context: We present a summary of the Second International Consultation on Bladder Cancer recommendations on chemotherapy for the treatment of bladder cancer using an evidence-based strategy. Objective: To review the data regarding chemotherapy in patients with clinically localized and metastatic bladder cancer with a focus on its use for patients in the neoadjuvant and adjuvant settings. Evidence acquisition: Medline databases were searched for original articles published prior to April 1, 2012, using the following search terms: bladder cancer, urothelial cancer, metastatic, advanced, neoadjuvant, and adjuvant therapy. Proceedings of major conferences from the last 5 yr also were searched. Novel and promising drugs currently in clinical trials were included. Evidence synthesis: The major findings are addressed in an evidence-based manner. Prospective trials and important cohort data were analyzed. Conclusions: Cisplatin-based combination chemotherapy for advanced and metastatic bladder cancer is an established standard, improving overall survival. In the advanced setting, cisplatin-ineligible patients may benefit from gemcitabine and carboplatin. Meta-analyses undertaken for neoadjuvant cisplatin-based combination chemotherapy show a 5% benefit in overall survival. Pathologic complete remission may be an intermediate surrogate for survival, but requires further validation. Use of neoadjuvant chemotherapy is low, and is attributable to patient and physician choice because of limited benefit, advanced age, and comorbidities including renal and/or cardiac dysfunction. Sufficient data to support adjuvant chemotherapy are lacking.

Original languageEnglish
Pages (from-to)58-66
Number of pages9
JournalEuropean Urology
Volume63
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Referral and Consultation
Carcinoma
Drug Therapy
Cisplatin
gemcitabine
Combination Drug Therapy
Survival
Neoadjuvant Therapy
Carboplatin
Adjuvant Chemotherapy
Meta-Analysis
Comorbidity
Clinical Trials
Databases
Physicians
Kidney
Pharmaceutical Preparations
Neoplasms
Therapeutics

Keywords

  • Adjuvant
  • Bladder cancer
  • Chemotherapy
  • Guidelines
  • Neoadjuvant
  • Recommendations

ASJC Scopus subject areas

  • Urology

Cite this

Sternberg, C. N., Bellmunt, J., Sonpavde, G., Siefker-Radtke, A. O., Stadler, W. M., Bajorin, D. F., ... Quinn, D. I. (2013). ICUD-EAU international consultation on bladder cancer 2012: Chemotherapy for urothelial carcinoma - Neoadjuvant and adjuvant settings. European Urology, 63(1), 58-66. https://doi.org/10.1016/j.eururo.2012.08.010

ICUD-EAU international consultation on bladder cancer 2012 : Chemotherapy for urothelial carcinoma - Neoadjuvant and adjuvant settings. / Sternberg, Cora N.; Bellmunt, Joaquim; Sonpavde, Guru; Siefker-Radtke, Arlene O.; Stadler, Walter M.; Bajorin, Dean F.; Dreicer, Robert; George, Daniel J.; Milowsky, Matthew I.; Theodorescu, Dan; Vaughn, David J.; Galsky, Matthew D.; Soloway, Mark S.; Quinn, David I.

In: European Urology, Vol. 63, No. 1, 01.01.2013, p. 58-66.

Research output: Contribution to journalArticle

Sternberg, CN, Bellmunt, J, Sonpavde, G, Siefker-Radtke, AO, Stadler, WM, Bajorin, DF, Dreicer, R, George, DJ, Milowsky, MI, Theodorescu, D, Vaughn, DJ, Galsky, MD, Soloway, MS & Quinn, DI 2013, 'ICUD-EAU international consultation on bladder cancer 2012: Chemotherapy for urothelial carcinoma - Neoadjuvant and adjuvant settings', European Urology, vol. 63, no. 1, pp. 58-66. https://doi.org/10.1016/j.eururo.2012.08.010
Sternberg, Cora N. ; Bellmunt, Joaquim ; Sonpavde, Guru ; Siefker-Radtke, Arlene O. ; Stadler, Walter M. ; Bajorin, Dean F. ; Dreicer, Robert ; George, Daniel J. ; Milowsky, Matthew I. ; Theodorescu, Dan ; Vaughn, David J. ; Galsky, Matthew D. ; Soloway, Mark S. ; Quinn, David I. / ICUD-EAU international consultation on bladder cancer 2012 : Chemotherapy for urothelial carcinoma - Neoadjuvant and adjuvant settings. In: European Urology. 2013 ; Vol. 63, No. 1. pp. 58-66.
@article{003eba3862bb4680af68e876a7733206,
title = "ICUD-EAU international consultation on bladder cancer 2012: Chemotherapy for urothelial carcinoma - Neoadjuvant and adjuvant settings",
abstract = "Context: We present a summary of the Second International Consultation on Bladder Cancer recommendations on chemotherapy for the treatment of bladder cancer using an evidence-based strategy. Objective: To review the data regarding chemotherapy in patients with clinically localized and metastatic bladder cancer with a focus on its use for patients in the neoadjuvant and adjuvant settings. Evidence acquisition: Medline databases were searched for original articles published prior to April 1, 2012, using the following search terms: bladder cancer, urothelial cancer, metastatic, advanced, neoadjuvant, and adjuvant therapy. Proceedings of major conferences from the last 5 yr also were searched. Novel and promising drugs currently in clinical trials were included. Evidence synthesis: The major findings are addressed in an evidence-based manner. Prospective trials and important cohort data were analyzed. Conclusions: Cisplatin-based combination chemotherapy for advanced and metastatic bladder cancer is an established standard, improving overall survival. In the advanced setting, cisplatin-ineligible patients may benefit from gemcitabine and carboplatin. Meta-analyses undertaken for neoadjuvant cisplatin-based combination chemotherapy show a 5{\%} benefit in overall survival. Pathologic complete remission may be an intermediate surrogate for survival, but requires further validation. Use of neoadjuvant chemotherapy is low, and is attributable to patient and physician choice because of limited benefit, advanced age, and comorbidities including renal and/or cardiac dysfunction. Sufficient data to support adjuvant chemotherapy are lacking.",
keywords = "Adjuvant, Bladder cancer, Chemotherapy, Guidelines, Neoadjuvant, Recommendations",
author = "Sternberg, {Cora N.} and Joaquim Bellmunt and Guru Sonpavde and Siefker-Radtke, {Arlene O.} and Stadler, {Walter M.} and Bajorin, {Dean F.} and Robert Dreicer and George, {Daniel J.} and Milowsky, {Matthew I.} and Dan Theodorescu and Vaughn, {David J.} and Galsky, {Matthew D.} and Soloway, {Mark S.} and Quinn, {David I.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.eururo.2012.08.010",
language = "English",
volume = "63",
pages = "58--66",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - ICUD-EAU international consultation on bladder cancer 2012

T2 - Chemotherapy for urothelial carcinoma - Neoadjuvant and adjuvant settings

AU - Sternberg, Cora N.

AU - Bellmunt, Joaquim

AU - Sonpavde, Guru

AU - Siefker-Radtke, Arlene O.

AU - Stadler, Walter M.

AU - Bajorin, Dean F.

AU - Dreicer, Robert

AU - George, Daniel J.

AU - Milowsky, Matthew I.

AU - Theodorescu, Dan

AU - Vaughn, David J.

AU - Galsky, Matthew D.

AU - Soloway, Mark S.

AU - Quinn, David I.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Context: We present a summary of the Second International Consultation on Bladder Cancer recommendations on chemotherapy for the treatment of bladder cancer using an evidence-based strategy. Objective: To review the data regarding chemotherapy in patients with clinically localized and metastatic bladder cancer with a focus on its use for patients in the neoadjuvant and adjuvant settings. Evidence acquisition: Medline databases were searched for original articles published prior to April 1, 2012, using the following search terms: bladder cancer, urothelial cancer, metastatic, advanced, neoadjuvant, and adjuvant therapy. Proceedings of major conferences from the last 5 yr also were searched. Novel and promising drugs currently in clinical trials were included. Evidence synthesis: The major findings are addressed in an evidence-based manner. Prospective trials and important cohort data were analyzed. Conclusions: Cisplatin-based combination chemotherapy for advanced and metastatic bladder cancer is an established standard, improving overall survival. In the advanced setting, cisplatin-ineligible patients may benefit from gemcitabine and carboplatin. Meta-analyses undertaken for neoadjuvant cisplatin-based combination chemotherapy show a 5% benefit in overall survival. Pathologic complete remission may be an intermediate surrogate for survival, but requires further validation. Use of neoadjuvant chemotherapy is low, and is attributable to patient and physician choice because of limited benefit, advanced age, and comorbidities including renal and/or cardiac dysfunction. Sufficient data to support adjuvant chemotherapy are lacking.

AB - Context: We present a summary of the Second International Consultation on Bladder Cancer recommendations on chemotherapy for the treatment of bladder cancer using an evidence-based strategy. Objective: To review the data regarding chemotherapy in patients with clinically localized and metastatic bladder cancer with a focus on its use for patients in the neoadjuvant and adjuvant settings. Evidence acquisition: Medline databases were searched for original articles published prior to April 1, 2012, using the following search terms: bladder cancer, urothelial cancer, metastatic, advanced, neoadjuvant, and adjuvant therapy. Proceedings of major conferences from the last 5 yr also were searched. Novel and promising drugs currently in clinical trials were included. Evidence synthesis: The major findings are addressed in an evidence-based manner. Prospective trials and important cohort data were analyzed. Conclusions: Cisplatin-based combination chemotherapy for advanced and metastatic bladder cancer is an established standard, improving overall survival. In the advanced setting, cisplatin-ineligible patients may benefit from gemcitabine and carboplatin. Meta-analyses undertaken for neoadjuvant cisplatin-based combination chemotherapy show a 5% benefit in overall survival. Pathologic complete remission may be an intermediate surrogate for survival, but requires further validation. Use of neoadjuvant chemotherapy is low, and is attributable to patient and physician choice because of limited benefit, advanced age, and comorbidities including renal and/or cardiac dysfunction. Sufficient data to support adjuvant chemotherapy are lacking.

KW - Adjuvant

KW - Bladder cancer

KW - Chemotherapy

KW - Guidelines

KW - Neoadjuvant

KW - Recommendations

UR - http://www.scopus.com/inward/record.url?scp=84870571565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870571565&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2012.08.010

DO - 10.1016/j.eururo.2012.08.010

M3 - Article

C2 - 22917984

AN - SCOPUS:84870571565

VL - 63

SP - 58

EP - 66

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -